13F filer · CIK 1263508
BAKER BROS. ADVISORS LP
NEW YORK, NY · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$20.0B
+$2.5B vs prior
Positions
84
New / sold out
9 / 9
Added / reduced
16 / 7
Turnover
2.9%
buys $827.7M · sells $541.6M
Top-10 weight
72.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Revolution Medicines, Inc. | +1,888,000 | +19.8% | +$353.6M |
| Added | Insmed Incorporated | +1,375,000 | +18.5% | +$146.6M |
| New | Celcuity Inc. | +30,750,000 | – | +$69.2M |
| Added | IDEAYA Biosciences, Inc. | +1,063,515 | +26.9% | +$39.6M |
| New | Faeth Therapeutics, Inc. | +1,286,411 | – | +$32.2M |
| Added | Relay Therapeutics, Inc. | +1,666,666 | +143.7% | +$31.2M |
| Added | AbCellera Biologics Inc. | +2,736,200 | +9.0% | +$21.5M |
| Added | Celldex Therapeutics, Inc. | +517,241 | +77.7% | +$19.2M |
| New | Cytokinetics, Incorporated | +211,267 | – | +$18.0M |
| New | Intellia Therapeutics, Inc. | +930,232 | – | +$15.7M |
15 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Edgewise Therapeutics, Inc. | -2,874,221 | -43.7% | $-116.8M |
| Sold out | Abivax S.A. | -875,796 | -100.0% | $-97.5M |
| Sold out | Celcuity Inc. | -30,750,000 | -100.0% | $-74.9M |
| Reduced | Summit Therapeutics Inc. | -3,604,715 | -9.9% | $-52.5M |
| Sold out | Spyre Therapeutics, Inc. | -1,000,000 | -100.0% | $-50.4M |
| Sold out | Centessa Pharmaceuticals plc | -670,751 | -100.0% | $-26.6M |
| Sold out | Immunocore Holdings plc | -734,397 | -100.0% | $-22.1M |
| Sold out | Contineum Therapeutics, Inc. | -1,420,838 | -100.0% | $-18.6M |
| Sold out | argenx SE | -25,174 | -100.0% | $-18.4M |
| Reduced | Immatics N.V. | -1,408,128 | -12.9% | $-14.3M |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Incyte CorporationCOM | 30,762,330 | $3.5B | 17.48% |
| 2 | BeOne Medicines Ltd.SPONSORED ADS | 8,801,567 | $2.5B | 12.57% |
| 3 | Revolution Medicines, Inc.COM | 11,443,357 | $2.1B | 10.74% |
| 4 | Madrigal Pharmaceuticals, Inc.COM | 2,143,131 | $1.2B | 5.77% |
| 5 | ACADIA Pharmaceuticals Inc.COM | 42,912,904 | $1.1B | 5.44% |
| 6 | Kymera Therapeutics, Inc.COM | 8,657,242 | $992.7M | 4.97% |
| 7 | Insmed IncorporatedCOM PAR $.01 | 8,796,111 | $937.8M | 4.70% |
| 8 | Celcuity Inc.COM | 7,915,792 | $828.2M | 4.15% |
| 9 | Kodiak Sciences Inc.COM | 19,919,186 | $776.1M | 3.89% |
| 10 | Rhythm Pharmaceuticals, Inc.COM | 5,604,483 | $622.3M | 3.12% |
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.